highperformr logo

AAVogen's Overview

Total employees1
HeadquartersSouth San Francisco
Founded2015

Aavogen is a biotechnology company dedicated to pioneering and developing novel adeno-associated virus (AAV) based gene therapies for a range of serious genetic and acquired diseases. The company leverages proprietary capsid engineering technologies and innovative vector designs to enhance the safety, efficacy, and deliverability of gene therapies. Aavogen's primary focus is on addressing unmet medical needs by translating cutting-edge scientific discoveries into potentially life-changing treatments for patients worldwide. Their research pipeline includes programs targeting rare diseases as well as more common conditions where gene therapy holds significant promise.

Where is AAVogen's Headquarters?

AAVogen officeAAVogen officeAAVogen officeAAVogen office
*Images sourced via web search. Rights belong to original owners

HQ Function

The headquarters serves as the central hub for Aavogen's research and development activities, corporate strategy, business development, and administrative operations.

Notable Features:

The facility likely includes state-of-the-art laboratories for AAV vector design, molecular biology, cell culture, and preclinical research, designed to foster innovation and collaboration.

Work Culture:

The work culture at Aavogen's headquarters is expected to be highly collaborative, science-driven, and fast-paced, with a strong emphasis on innovation, scientific rigor, and a patient-centric mission. Employees likely share a passion for advancing gene therapy.

HQ Significance:

Locating in South San Francisco provides Aavogen with access to a rich ecosystem of leading academic institutions, experienced biotech talent, venture capital, and potential collaborators, crucial for a company in the gene therapy space.

Values Reflected in HQ: The headquarters' design and operations would aim to reflect Aavogen's core values such as innovation, scientific excellence, collaboration, and a commitment to developing transformative therapies.

Location:

While Aavogen's primary physical operations are concentrated in the United States (South San Francisco, CA and potentially Gaithersburg, MD), its impact and collaborations are global. The company engages with international research institutions, partners with contract manufacturing organizations (CMOs) and contract research organizations (CROs) globally for its development programs, and aims to serve patients worldwide with its future therapies. Clinical trials, as they advance, will likely involve sites in multiple countries.

Street Address:

250 E Grand Ave, Suite 70

City:

South San Francisco

State/Province:

CA

Country:

USA

AAVogen's Global Presence

Gaithersburg, MD, USA

Address: 2 W dislocations, Gaithersburg, MD 20878, USA (Note: Address search points to this general area based on some directory listings, specific suite unknown)

To facilitate engagement with East Coast research institutions, contract research organizations (CROs), and regulatory bodies, expanding Aavogen's operational footprint and access to specialized talent.

Buying Intent Signals for AAVogen

Highperformr Signals uncover buying intent and give you clear insights to target the right accounts at the right time — helping your sales, marketing, and GTM teams close more deals, faster.

Notable news
Hiring actively
Corporate Finance
Corporate Finance
Corporate Finance
Corporate Finance
Corporate Finance
*Example signal, not calculated in real time

Executive Team of AAVogen

As of April 2025, AAVogen' leadership includes:

Clague P. Hodgson, Ph.D. - Founder, President, CEO & CSO
Frank Gleeson - Chief Operating Officer
Jason Fewell, PhD - Vice President, Research & Development

Investors of AAVogen

AAVogen has been backed by several prominent investors over the years, including:

National Institutes of Health (NIH) - via SBIR grants
Foundation Fighting Blindness
Private Equity/Angel Investors (details often undisclosed for private companies)

Executive New Hires/Exits in the Last 12 Months

Hire0
Exits0

Information on executive hires or exits in the last 12 months is not readily available in public sources. Private companies like Aavogen often do not publicly announce all executive changes unless they are of major significance or part of a funding/IPO announcement.

Technology (Tech Stack) used by AAVogen

Discover the tools AAVogen uses. Highperformr reveals the technologies powering your target accounts — helping your sales, marketing, and GTM teams prioritize smarter and close faster.

AAVogen Email Formats and Examples

Based on common biotech industry patterns and available contact information, Aavogen likely uses email formats such as [first_initial][last]@aavogen.com or [first].[last]@aavogen.com.

[first_initial][last]@aavogen.com

Format

chodgson@aavogen.com

Example

80%

Success rate

News and media

PR NewswireSeptember 1, 2021

Aavogen Announces Non-Human Primate Data Demonstrating Robust Expression and Efficacy Following a Single Intravitreal Injection of Novel Gene Therapy AVG-001A for Wet AMD

Aavogen, Inc. presented data at the 21st Annual Meeting of the Angiogenesis, Exudation, and Degeneration 2021 virtual conference, showcasing promising results for its AVG-001A gene therapy candidate in treating wet age-related macular degeneration (AMD) in non-human primates....more

PR NewswireJanuary 7, 2020

Aavogen Announces Research Collaboration With Massachusetts Eye and Ear To Advance Novel Gene Therapy for Dry Age-Related Macular Degeneration

Aavogen, Inc. announced a research collaboration with Massachusetts Eye and Ear to develop a novel gene therapy for dry age-related macular degeneration (AMD), leveraging Aavogen's proprietary AAV technology platform....more

Foundation Fighting BlindnessJuly 13, 2023

Foundation Fighting Blindness Invests $1 Million in Aavogen for Development of Novel Gene Therapy for Stargardt Disease

The Foundation Fighting Blindness, through its Retinal Degeneration Fund, has invested $1 million in Aavogen to support the preclinical development of a novel AAV gene therapy for Stargardt disease, the most common form of inherited macular degeneration....more

Highperformr’s free tools for company research

Explore Employees by Region or Country

See where a company’s workforce is located, by country or region.

View Funding Details

View past and recent funding rounds with amounts and investors.

Understand Revenue Insights

Understand company revenue estimates and financial scale.

Track Active Job Openings

Track active roles and hiring trends to spot growth signals.

Review Product and Offerings

Discover what a company offers—products, platforms, and solutions.

Get SIC or NAICS Codes

Get the company’s official SIC and NAICS classifications.

Analyze Website Traffic Trends

Analyze visitor volume, engagement, and top traffic sources.

Discover Social Profiles and Engagement

Explore LinkedIn, Twitter, and other active social profiles.

Identify Top Competitors

Identify top competitors based on similar business traits.

Research and Discover Companies with Highperformr — Smarter, Faster

Explore companies in depth — from the tech they use to recent funding, hiring trends, and buyer signals — all in one powerful view.

Highperformr AI helps you surface the right accounts and enrich your CRM with verified company and contact insights, so your teams can prioritize and engage faster.

  • Track intent signals to find buyers who are actively in-market
  • Enrich contacts and companies instantly, no need to switch tools
  • Automate workflows to stay ahead of every change
  • Connect your CRM & tools for seamless data sync and activation

Thousands of companies, including AAVogen, are just a search away.